I'm also confident that the additional data will be supportive of continued development. This additional data will show that the early data in stage IV lymphoma patient with complete response was not a fluke and I believe provide a very clear signal that the drug is working as expected. Market has decided it wants to see the additional data before buying fully into the Avastin+Rindo combination potential which is why we are locked here in limbo until the data and conference call. I expect we will get the juicy details about the plans moving forward as a result of the data. Should be very interesting. We'll see if this is enough to take the brakes off of the share price momentum. Should be, but I thought for sure CDX-1127 data would have knocked the socks off of the analysts and fund buyers. We'll see.
Well, I keep wondering,- since the results will be presented on the meeting, why to have CC after that? It must be something regulatory or else not directly related to scientific presentations. So, I'm also encouraged. And, if the results will be in line will CDX-1127 (exceeded expectations)+CC with something "in line of our new dramatic improvement (in whatever is to improve) we expect to file NDA 1-1.5 years before initially scheduled",- then, I believe we'll get to $35+.
I'll be in DR until Dec 1, and I tend not to use internet and/or TV on vacation, so I'll get the whole story in one shot! Just hope it will be good one!
you'd think if the drug is saving lives in this difficult to treat patient population and study is robust enough that Rindo could get breakthrough status in this poulation. It's unclear to me if Celldex needs to request a review for this to happen or not.